Ampicillin

Probiotic Study Shows Promise on Improving Innate Immunity

Retrieved on: 
Tuesday, September 5, 2023

TROY, Va., Sept. 5, 2023 /PRNewswire/ -- BIO-CAT, Inc ,  | BIO-CAT announced today that a newly published study on the probiotic Bacillus subtilis MB40 revealed promising results leading to the reduction of Listeria.

Key Points: 
  • TROY, Va., Sept. 5, 2023 /PRNewswire/ -- BIO-CAT, Inc ,  | BIO-CAT announced today that a newly published study on the probiotic Bacillus subtilis MB40 revealed promising results leading to the reduction of Listeria.
  • The study was designed to determine the effects of Bacillus subtilis MB40 supplementation on innate immunity and Listeria.
  • This study was completed in partnership with the School of Animal Sciences at Virginia Tech in Blacksburg, Virginia.
  • It was encouraging to see that the inclusion of Bacillus subtilis MB40 spores in the diet helped improve innate immunity."

Piramal Critical Care Launches First to Market Generic Zinc Sulfate Injection in the U.S.

Retrieved on: 
Thursday, August 18, 2022

MUMBAI, India, Aug. 18, 2022 /PRNewswire/ --Piramal Pharma Limited's Critical Care business, a leading Complex Hospital Generics company, announces First to Market Generic U.S. launch of Zinc Sulfate Injection.

Key Points: 
  • MUMBAI, India, Aug. 18, 2022 /PRNewswire/ --Piramal Pharma Limited's Critical Care business, a leading Complex Hospital Generics company, announces First to Market Generic U.S. launch of Zinc Sulfate Injection.
  • Zinc Sulfate is a trace element indicated as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
  • Zinc Sulfate Injection joins our growing US portfolio of injectable products, complementing our market-leading inhaled anesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world."
  • In addition to the recent launch of Zinc Sulfate injection, over the past several years PCChas launched a broad line of critical generic injectables in the U.S. market, including Ampicillin and Sulbactam for Injection, USP, Dexmedetomidine Injection, USP, Dexmedetomidine HCl Injection, USP, Glycopyrrolate Injection, USP, Rocuronium Bromide Injection, and Succinylcholine Chloride Injection, USP.

TrippBio announces publication of data supporting the antiviral potency of TD-213 against SARS-CoV-2 in Scientific Reports

Retrieved on: 
Monday, September 13, 2021

These results are being used to design appropriate clinical trials to evaluate the efficacy of TD-213 as a treatment for mild-to-moderate COVID-19.

Key Points: 
  • These results are being used to design appropriate clinical trials to evaluate the efficacy of TD-213 as a treatment for mild-to-moderate COVID-19.
  • "These data demonstrate a very potent antiviral effect of TD-213 against SARS-CoV-2," said Ralph Tripp, PhD.
  • Probenecid is a favorable antiviral drug candidate as it is commercially available and has high plasma concentrations with a benign clinical safety profile.
  • TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and professor at the University of Georgia.

Emmes Study Leads to Pediatric Drug Labeling Change for Ampicillin

Retrieved on: 
Tuesday, January 21, 2020

FDA's approval was based in part on a National Institute of Child Health and Human Development (NICHD)-funded study , conducted under the Best Pharmaceuticals for Children Act (BPCA).

Key Points: 
  • FDA's approval was based in part on a National Institute of Child Health and Human Development (NICHD)-funded study , conducted under the Best Pharmaceuticals for Children Act (BPCA).
  • Emmes provided full-service data management, regulatory support, pharmacovigilance, site monitoring, and statistical analyses for the ampicillin study, and facilitated the study protocol design.
  • Emmes is in the third year of a 10-1/2 year contract supporting pediatric clinical trials aimed at improving the labeling of drugs for pediatric use.
  • Ampicillin is one of the newest drug labeling changes resulting from study data submitted to and approved by the FDA, and it represents another step forward in helping doctors safely prescribe medication to their youngest patients."